TheraRadar
Data updated: Jun 28, 2026

CLEOCIN (clindamycin palmitate hydrochloride) · PHARMACIA AND UPJOHN

Infectious Disease Approved 1980-07-09

CLEOCIN Vaginal Ovules are indicated for 3-day treatment of bacterial vaginosis in non-pregnant women. There are no adequate and well-controlled studies of CLEOCIN Vaginal Ovules in pregnant women. NOTE: For purposes of this indication, a clinical diagnosis of bacterial vaginosis is usually defined by the presence of a homogeneous vaginal discharge that (a) has a pH of greater than 4.

6
Indications
--
Phase 3 Trials
46
Years on Market

Details

Status
Discontinued
First Approved
1980-07-09
Routes
ORAL, TOPICAL, VAGINAL
Dosage Forms
FOR SOLUTION, SWAB, CREAM, CAPSULE, SUPPOSITORY

CLEOCIN Approval History

1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
80 FDA actions from 1980 to 2026 · 2 indication expansions
May 2026 SUPPL
Label · Labeling
Nov 2025 SUPPL
Label · Labeling
Jul 2022 SUPPL
Label · Labeling

What CLEOCIN Treats

1 indications

CLEOCIN is approved for 1 conditions since its original approval in 1980. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Bacterial Vaginosis
Source: FDA Label

CLEOCIN Competitive Set

Pro

Three rings of competition based on shared molecular targets and treated indications.

MoA expansion candidates

3

Same target(s), different indications — where else is this mechanism being explored?

Indication competitors

3

Same indication, different mechanism — what else might this patient receive?

Unlock 2 more competitors across all three rings.
Upgrade to Pro

Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.

Drugs Similar to CLEOCIN

3 of 7

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

CLINDESSE
CLINDAMYCIN PHOSPHATE
1 shared
PADAGIS US
Shared indications:
Bacterial Vaginosis
NUVESSA
METRONIDAZOLE
1 shared
ALEMBIC THERAP
Shared indications:
Bacterial Vaginosis
SOLOSEC
SECNIDAZOLE
1 shared
EVOFEM INC
Shared indications:
Bacterial Vaginosis
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

CLEOCIN FDA Label Details

Indications & Usage

FDA Label (PDF)

CLEOCIN Vaginal Ovules are indicated for 3-day treatment of bacterial vaginosis in non-pregnant women. There are no adequate and well-controlled studies of CLEOCIN Vaginal Ovules in pregnant women. NOTE: For purposes of this indication, a clinical diagnosis of bacterial vaginosis is usually defined by the presence of a homogeneous vaginal discharge that (a) has a pH of greater than 4.5, (b) emits a "fishy" amine odor when mixed with a 10% KOH solution, and (c) contains clue cells on microscopic examination. Gram's stain results consistent with a diagnosis of bacterial vaginosis include (a) mar...

Track CLEOCIN with TheraRadar Pro

Watchlist alerts, full database access, CSV exports across 14,000+ drugs.

Upgrade to Pro

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.